Pharmaceuticals

Fulcrum Therapeutics

Fulcrum Therapeutics released FY2026 Q1 earnings on April 27 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2478 (forecast USD -0.3016)

Fulcrum Therapeutics to Release FY2026 Q1 Earnings on April 27 Pre-Market EST, Forecast EPS -0.3016 USD

Fulcrum Therapeutics released FY2025 Annual Earnings on February 24 Pre-Market EST, Actual Revenue USD 0 (Forecast USD 0), Actual EPS USD -1.1819 (Forecast USD -1.1727)

Fulcrum Therapeutics released FY2025 Q4 earnings on February 24 Pre-Market EST, with actual EPS of USD -0.3112 (forecasted EPS USD -0.3053)

Fulcrum Therapeutics to Release FY2025 Q4 Earnings on February 24, 2026, Pre-Market EST; Forecasted EPS: USD -0.3053

Fulcrum Therapeutics Inc. Highlights Promise of Pociredir in Sickle Cell Disease Treatment and Plans FDA Meeting

Robert J. Gould Sold Common Stock of Fulcrum Therapeutics Inc.

RA Capital Management Sells Fulcrum Therapeutics Common Stock

HC Wainwright Raises Fulcrum Therapeutics Earnings Estimate to $0.94 and Sets $25 Target Price

Fulcrum Therapeutics Expands Initial Public Offering

Fulcrum Therapeutics released FY2025 9 Months Earnings on October 29 Pre-Market EST, with actual revenue of USD 0 and EPS of USD -0.8756

Fulcrum Therapeutics released FY2025 Q3 earnings on October 29 Pre-Market (EST), actual revenue USD 0, actual EPS USD -0.313 (forecast EPS USD -0.29)

Fulcrum Therapeutics Inc. Reports Positive Clinical Trial Results for Pociredir

Schwartz Reiterates Moderate Buy Rating on Fulcrum Therapeutics

Fulcrum Therapeutics to Release FY2025 Q3 Earnings on October 29, Pre-Market EST, Forecast EPS USD -0.29

Fulcrum Therapeutics Grants Rights

Analyst Schwartz analyzes the healthcare industry and rates Fulcrum Therapeutics stock

Kluska Maintains Buy Rating for Fulcrum Therapeutics

Fulcrum Therapeutics released FY2025 Semi-Annual Earnings on July 29 (EST), actual revenue USD 0, actual EPS USD -0.56

Fulcrum Therapeutics released FY2025 Q2 earnings on July 29 (EST), actual EPS USD -0.28 (forecast USD -0.2942)

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

FULC

Fulcrum Therapeutics announced that Greg Tourangeau will depart as Vice President, Finance and principal accounting officer by mutual agreement. Concurrently, the company agreed to retention payments for CEO Alex Sapir, CFO Alan Musso, and Chief Legal Officer Curtis Oltmans. These measures aim to preserve capital following the discontinuation of pociredir development. The executive agreements include enhanced Change in Control benefits.

TradingView

Fulcrum Therapeutics' Greg Tourangeau to Depart; Sapir, Musso and Oltmans Receive Retention Payments

KMDA

CING

DRTS

MSFT

This week, the biotech sector saw FDA approvals for Philips' AI ultrasound and Lupin's oncology/ophthalmology drugs, while Kamada gained approval for a rabies testing lab. Fulcrum halted its sickle cell program due to malignancy risks, and Cingulate received an FDA complete response letter for its ADHD drug. Key deals included ResMed acquiring Noctrix Health, Mayo Clinic partnering with Microsoft on healthcare AI, and Alpha Tau collaborating with Tolmar for prostate cancer therapy.

- This week, the U.S. biotech sector experienced significant regulatory activity, including FDA approvals for several therapies, study halts, and strategic collaborations.  
- Notable approvals included Philips' Elevate Plus for ultrasound and Lupin's dual FDA approvals in oncology, while Fulcrum Therapeutics halted its Pociredir program due to safety concerns.  
- Positive clinical trial data was reported across various cancer treatments, demonstrating advancements and potential in key therapeutic areas.

rttnews

NOVARTIS AG

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

Kamada

Koninklijke Philips Elect

Resmed

Cingulate

Alpha Tau Medical

Microsoft

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals

United Imaging Healthcare

Bluejay Diagnostics

Koninklijke Philips N.V.

CINGULATE INC C/WTS 10/12/2026 (TO PUR COM)

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN

Levi & Korsinsky is investigating Fulcrum Therapeutics (FULC) for potential securities fraud after its stock plunged 50% on June 1, 2026. The drop followed FDA safety concerns regarding malignancy risks linked to the PRC2 inhibitor class, leading Fulcrum to discontinue its lead candidate, pociredir. The firm examines whether prior statements about the drug's safety were misleading.

MorningStar

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

Fulcrum Therapeutics halted development of its lead drug pociredir due to FDA concerns over malignancy risks associated with the PRC2 pathway. Consequently, the company has initiated a strategic review to explore options such as mergers or acquisitions. Despite the negative news, shares rose slightly on Thursday amid bearish technical trends and recent analyst downgrades.

benzinga_article

JPMorgan Chase

Stifel Financial

Piper Sandler Cos

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

What's Going On With Fulcrum Therapeutics Stock On Thursday?

SARO

TMHC

Wall Street analysts downgraded several stocks on Tuesday. Stifel and Piper Sandler downgraded Fulcrum Therapeutics (FULC) to Hold/Underweight with price targets of $3. Truist Securities downgraded Taylor Morrison Home (TMHC) to Hold, maintaining a $72.50 target, and also downgraded FULC to Hold with a $4 target. Jefferies downgraded StandardAero (SARO) to Hold, cutting its target to $30.

Standardaero

Taylor Morrison Home

Truist Financial

Jefferies Financial

This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Levi & Korsinsky has initiated an investigation into Fulcrum Therapeutics (FULC) regarding potential securities law violations. The probe focuses on whether the company made misleading statements about its pociredir program's Phase III prospects while maintaining significant financial commitments, such as a $25.1 million lease, before discontinuing the drug due to FDA safety concerns. This disclosure caused FULC's stock to drop approximately 50% in a single session.

prnewswire

CAMP4 Therapeutics

16:58 ETFulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)